Researcher’s, “Bullous pemphigoid - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Bullous pemphigoid pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Bullous pemphigoid Understanding
Bullous pemphigoid: Overview
Bullous pemphigoid (BP) is a rare, autoimmune, chronic skin disorder characterized by blistering, urticarial lesions (hives) and itching. Less commonly these blisters can involve the mucous membranes including the eyes, oral mucosa, esophagus and genital mucosa. It typically presents in older adults as a generalized intensely itchy blistering skin condition. The first symptom of BP is usually redness and itching of the skin. Within weeks to months, thin-walled, tense blisters with clear fluid centers (bullae) appear on the arms and legs (flexor surfaces), in the armpits (axillae), on the abdomen, and/or in the skinfolds of the groin. Mucous membranes may also be involved but are less commonly seen than skin blisters.

"Bullous pemphigoid - Pipeline Insight, 2021" report by Researcher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bullous pemphigoid pipeline landscape is provided which includes the disease overview and Bullous pemphigoid treatment guidelines. The assessment part of the report embraces, in depth Bullous pemphigoid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bullous pemphigoid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Bullous pemphigoid R&D. The therapies under development are focused on novel approaches to treat/improve Bullous pemphigoid.

Bullous pemphigoid Emerging Drugs Chapters
This segment of the Bullous pemphigoid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bullous pemphigoid Emerging Drugs
• Benralizumab: AstraZeneca
Interleukin-5 (IL-5) induces an eosinophil-mediated inflammatory response by binding to the IL-5 receptor (IL-5R) expressed in eosinophils, basophils and some mast cells. Benralizumab, unlike IL-5 low-affinity binding, binds with high affinity to the domain I of the α-chain of IL-5R and blocks its signaling and the proliferation of IL-5-dependent cell lines. On the other hand, Benralizumab is an afucosylated antibody in the CH2 region which gives it a high affinity for the FcγRIIIa on natural killer cells, macrophages and neutrophils. This binding triggers a magnified apoptosis response in eosinophils via antibody-dependent cell-mediated cytotoxicity. Currently, it is in Phase III stage of clinical trial evaluation to treat Bullous Pemphigoid.

• Dupilumab: Regeneron/Sanofi
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling. Dupilumab (Dupixent) is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. The drug is in Phase III clinical studies for Bullous Pemphigoid. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. Dupilumab was invented using Regeneron's proprietary VelocImmune technology. The FDA has granted orphan drug designation to Dupilumab or the treatment of Bullous Pemphigoid.
Further product details are provided in the report……..

Bullous pemphigoid: Therapeutic Assessment
This segment of the report provides insights about the different Bullous pemphigoid drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Bullous pemphigoid
There are approx. 8+ key companies which are developing the therapies for Bullous pemphigoid. The companies which have their Bullous pemphigoid drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

• Phases
Researcher’s report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Bullous pemphigoid pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bullous pemphigoid: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bullous pemphigoid therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bullous pemphigoid drugs.

Bullous pemphigoid Report Insights
• Bullous pemphigoid Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bullous pemphigoid Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Bullous pemphigoid drugs?
• How many Bullous pemphigoid drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bullous pemphigoid?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bullous pemphigoid therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bullous pemphigoid and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• AstraZeneca
• Regeneron
• Alkahest
• Akari Therapeutics
• Immune Pharmaceuticals
• Eli Lilly and Company
• Amgen
• TWi Biotechnology

Key Products
• Benralizumab
• Dupilumab
• Lazucirnon
• Nomacopan
• Bertilimumab
• Ixekizumab
• Apremilast
• Diacerein